CPT® Code 87913

Infectious agent genotype analysis by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), mutation identification in targeted region(s)

Infectious agent genotype analysis by nucleic acid, specifically for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), involves the identification of mutations within targeted regions of the virus's genetic material. This process is crucial for understanding the evolution and transmission dynamics of the virus, particularly in the context of the ongoing coronavirus disease (COVID-19) pandemic. Genotyping SARS-CoV-2 isolates allows researchers and healthcare professionals to monitor genetic variations that may impact the virus's behavior, including its transmissibility and potential resistance to vaccines. The analysis is particularly relevant for patients who have contracted COVID-19 despite being fully vaccinated, as it helps in identifying any mutations that may contribute to vaccine escape. The procedure typically begins with a specimen collected from a nasopharyngeal swab, which is tested for the presence of SARS-CoV-2 RNA. Following this, the viral nucleic acid is extracted and purified, setting the stage for reverse transcription polymerase chain reaction (RT-PCR) testing. This sophisticated technique involves converting the viral RNA into complementary DNA (cDNA) and amplifying it to detect specific genetic markers. The use of labeled DNA probes during the hybridization process enables the identification of nucleotide base substitutions, which are critical for determining the genetic profile of the virus and understanding its potential implications for public health and vaccine efficacy.